Format

Send to

Choose Destination
See comment in PubMed Commons below
Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.

A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study.

Author information

1
1] Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan [2] Division for Counseling and Support, The University of Tokyo, Tokyo, Japan.
2
Department of Molecular Psychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
3
Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
4
1] Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan [2] Department of Child Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
5
Human Metabolome Technologies, Tsuruoka, Japan.
6
1] Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan [2] Japan Science and Technology Agency, CREST, Tokyo, Japan.
7
1] Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan [2] Japan Science and Technology Agency, National Bioscience Database Center (NBDC), Tokyo, Japan.

Abstract

Few biomarkers have been known that can easily measure clinical conditions in mental illnesses such as schizophrenia. Capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) is a new method that can measure ionized and low-molecular-weight metabolites. To explore global metabolomic alterations that characterize the onset of schizophrenia and identify biomarkers, we profiled the relative and absolute concentrations of the plasma metabolites from 30 patients with first-episode schizophrenia (FESZ, four drug-naïve samples), 38 healthy controls and 15 individuals with autism spectrum disorders using CE-TOFMS. Five metabolites had robust changes (increased creatine and decreased betaine, nonanoic acid, benzoic acid and perillic acid) in two independent sample sets. Altered levels of these metabolites are consistent with well-known hypotheses regarding abnormalities of the homocysteine metabolism, creatine kinase-emia and oxidative stress. Although it should be considered that most patients with FESZ received medication, these metabolites are candidate biomarkers to improve the determination of diagnosis, severity and clinical stages, especially for FESZ.

PMID:
24713860
PMCID:
PMC4012283
DOI:
10.1038/tp.2014.19
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center